Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 19/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7895325 | 0.89 | SLC6A9 (0.59) | SLC6A9 | |
| Hydrochloric Acid SCHEMBL3103386 | 0.88 | SLC6A9 (0.58) | SLC6A9 | |
| SCHEMBL13097395 | 0.85 | SLC6A9 (0.56) | SLC6A9KCNH2 | |
| SCHEMBL7898514 | 0.79 | SLC6A9 (0.60) | SLC6A9KCNH2 | |
| Hydrochloric Acid SCHEMBL3101039 | 0.78 | SLC6A9 (0.60) | SLC6A9KCNH2 | |
| SCHEMBL7885730 | 0.77 | SLC6A9 (0.46) | SLC6A9 | |
| SCHEMBL7893234 | 0.77 | SLC6A9 (0.68) | SLC6A9KCNH2 | |
| SCHEMBL13097394 | 0.76 | SLC6A9 (0.57) | SLC6A9KCNH2 | |
| Hydrochloric Acid SCHEMBL3101293 | 0.76 | SLC6A9 (0.67) | SLC6A9KCNH2 | |
| SCHEMBL7893076 | 0.75 | SLC6A9 (0.62) | SLC6A9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | AADAT, GFPT1, BCAT1 | SLC6A9 23/4885CARM1 2104/4885PRMT6 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.